Evidence map›Paper›PMID 33828497›Full record

ReviewFrontiers in psychiatry2021

Alcohol Use Disorder in the Age of Technology: A Review of Wearable Biosensors in Alcohol Use Disorder Treatment.

Rachel E Davis-Martin, Sheila M Alessi, Edwin D Boudreaux

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
7.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Detecting Ethanol Intoxication and Impairment Using Wearable Biosensors.Proceedings of the ... Annual Hawaii International Conference on System Sciences. Annual Hawaii International Conference on System Sciences · 2026
    Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Rachel E Davis-MartinDepartment of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA, United States.
Sheila M AlessiDepartment of Medicine, Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, United States.
Edwin D BoudreauxDepartment of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA, United States.
University of Massachusetts Chan Medical School · USUniversity of Connecticut · US

Funding

Pilot StudiesP50AA027055 · NIAAA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI COVAULT, JONATHAN M · 2019 to 2023
$7.8M
Telehealth to Improve Prevention of Suicide (TIPS) in EDsR01MH124685 · NIMH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BOUDREAUX, EDWIN D · 2021 to 2024
$4.4M
Deriving a Clinical Decision Rule for Suicide Risk in the Emergency Department SettingR01MH118220 · NIMH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BOUDREAUX, EDWIN D, WANG, BO · 2019 to 2022
$3.9M
POST-DOCTORAL TRAINING PROGRAM IN ALCOHOL STUDIEST32AA007290 · NIAAA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI SHEILA MARIE ALESSI · 1985 to 2026
$3.2M
Interventions for Unemployed Hazardous DrinkersR01AA023502 · NIAAA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI ALESSI, SHEILA MARIE, RASH, CARLA J · 2015 to 2019
$3.1M
Computerized Adaptive Suicidal Risk Stratification and PredictionR44MH118780 · NIMH · ADAPTIVE TESTING TECHNOLOGIES · PI BOUDREAUX, EDWIN D, COHEN, YEHUDA · 2019 to 2022
$1.9M
Reward-based technology to improve opioid use disorder treatment initiation after an ED visitR42DA049448 · NIDA · Q2I, LLC · PI BOUDREAUX, EDWIN D · 2019 to 2023
$1.7M
Emotional Influences on Diagnostic Error in Emergency Medicine: An Experimental Approach to Understand Diagnostic Failure and Facilitate Improvement for Patients with and without Mental IllnessR01HS025752 · AHRQ · UNIVERSITY OF MASSACHUSETTS AMHERST · PI ISBELL, LINDA M · 2017 to 2021
$1.7M
Technology-Assisted Systems Change for Suicide Prevention (TASCS)R34MH123578 · NIMH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LARKIN, CELINE, TULU, BENGISU · 2020 to 2020
$727k
AHRQ HHS R01 HS025752NIAAA NIH HHS P50 AA027055NIAAA NIH HHS R01 AA023502NIAAA NIH HHS T32 AA007290NIDA NIH HHS R42 DA049448NIMH NIH HHS R01 MH118220NIMH NIH HHS R01 MH124685NIMH NIH HHS R34 MH123578NIMH NIH HHS R44 MH118780
6 · The paper itself

Abstract

Biosensors enable observation and understanding of latent physiological occurrences otherwise unknown or invasively detected. Wearable biosensors monitoring physiological constructs across a wide variety of mental and physical health conditions have become an important trend in innovative research methodologies. Within substance use research, explorations of biosensor technology commonly focus on identifying physiological indicators of intoxication to increase understanding of addiction etiology and to inform treatment recommendations. In this review, we examine the state of research in this area as it pertains to treatment of alcohol use disorders specifically highlighting the gaps in our current knowledge with recommendations for future research. Annually, alcohol use disorders affect approximately 15 million individuals. A primary focus of existing wearable technology-based research among people with alcohol use disorders is identifying alcohol intoxication. A large benefit of wearable biosensors for this purpose is they provide continuous readings in a passive manner compared with the gold standard measure of blood alcohol content (BAC) traditionally measured intermittently by breathalyzer or blood draw. There are two primary means of measuring intoxication with biosensors: gait and sweat. Gait changes have been measured via smart sensors placed on the wrist, in the shoe, and mobile device sensors in smart phones. Sweat measured by transdermal biosensors detects the presence of alcohol in the blood stream correlating to BAC. Transdermal biosensors have been designed in tattoos/skin patches, shirts, and most commonly, devices worn on the ankle or wrist. Transdermal devices were initially developed to help monitor court-ordered sobriety among offenders with alcohol use disorder. These devices now prove most useful in continuously tracking consumption throughout clinical trials for behavioral treatment modalities. More recent research has started exploring the uses for physical activity trackers and physiological arousal sensors to guide behavioral interventions for relapse prevention. While research has begun to demonstrate wearable devices' utility in reducing alcohol consumption among individuals aiming to cutdown on their drinking, monitoring sustained abstinence in studies exploring contingency management for alcohol use disorders, and facilitating engagement in activity-based treatment interventions, their full potential to further aid in understanding of, and treatment for, alcohol use disorders has yet to be explored.

Indexed as

alcohol use disordercontingency managementtransdermal alcohol contenttreatmentwearable biosensors

Identifiers

PMID33828497
PMCPMC8019775
OpenAlexW3137127954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.